Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2020-06-01 Capital/Financing Update
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received
Capital/Financing Update Classification · 1% confidence The document announces a specific corporate event: receiving a second installment of an upfront payment from a collaboration/licensing agreement with Biotheus Inc. This concerns financial milestones related to a drug development partnership. This type of announcement, detailing financing, licensing payments, or capital structure updates, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific financial/strategic transaction milestone. The document length (3414 chars) is substantial enough to be the primary announcement, not just a placeholder for a larger report.
2020-06-01 English
Alligator Bioscience presenterar ATOR-1015 på ASCO: Ytterligare positiva fas I-data för den bispecifika CTLA-4 x OX40-antikroppen
Investor Presentation Classification · 1% confidence The document is a press release dated May 29, 2020, announcing that Alligator Bioscience is presenting positive Phase I clinical trial data for their drug candidate ATOR-1015 at the ASCO Annual Meeting. It details safety results, dose escalation, and future plans. This type of announcement, focusing on clinical trial updates and scientific presentation disclosures, is characteristic of an Investor Presentation (IP) or a general announcement related to investor relations/clinical progress. Since it is a formal announcement of data being presented at a conference, and not the full financial report (10-K) or a standalone audit report (AR), the most fitting category is Investor Presentation (IP), as it is material intended for investors regarding clinical progress. It is not a general regulatory filing (RNS) because it fits the specific 'IP' definition better, nor is it an Earnings Release (ER) as it concerns clinical data, not periodic financial results.
2020-05-29 Swedish
Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015
Regulatory Filings Classification · 1% confidence The document is an announcement by Alligator Bioscience regarding the presentation of novel Phase I clinical trial data for their drug candidate ATOR-1015 at the ASCO Annual Meeting. It details safety findings, dose escalation, and future plans. This type of announcement, which communicates specific clinical trial updates and results outside of a formal quarterly/annual report or a standard earnings release, fits best under the general category of Investor Relations or a specific regulatory announcement. Since it is not a full financial report (10-K, IR), a formal earnings release (ER), or a transcript (CT), and it relates to ongoing development and clinical progress, it is most appropriately classified as an Investor Presentation (IP) if it were the presentation itself, or a general Regulatory Filing (RNS) as it is a press release detailing material company information. Given the content is a press release announcing data presentation, and it is not a formal financial report, RNS is the most suitable fallback for a material, non-standard announcement. However, since it is announcing clinical data which is often presented in an Investor Presentation format, and the text itself reads like a summary of what was presented, IP is a strong candidate. Given the context of a press release announcing data presented elsewhere, RNS (Regulatory Filings/General Announcement) is often used for such material updates that aren't strictly financial results or formal statutory filings. I will lean towards RNS as it is a general press release about company activity, though IP is closely related.
2020-05-29 English
Kommuniké från årsstämma den 5 maj 2020 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled "Kommuniké från årsstämma den 5 maj 2020 i Alligator Bioscience AB" (Communication from the Annual General Meeting held on May 5, 2020, in Alligator Bioscience AB). It explicitly summarizes the decisions made during the AGM, including the approval of accounts, discharge of directors, election of the board and auditor, remuneration guidelines, authorization for share issues, and amendments to the articles of association. This content directly corresponds to the materials and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). The document length (4754 chars) is substantial enough to be the summary itself, not just a brief announcement of publication.
2020-05-05 Swedish
Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2020
AGM Information Classification · 1% confidence The document explicitly states it is a "Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2020" and summarizes the resolutions adopted during that meeting, including adoption of accounts, discharge from liability, election of board members and auditor, remuneration, and authorization regarding share issues. This content directly corresponds to the materials presented or summarized at an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2020-05-05 English
Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR
Earnings Release Classification · 1% confidence The document is an announcement from Alligator Bioscience regarding the presentation of interim Phase I clinical trial data for their drug candidate ATOR-1015 at the AACR Annual Meeting. It details safety findings, dosing levels, and adverse events. This content is characteristic of an Earnings Release (ER) or a specific clinical update that functions similarly to an ER by releasing key performance/progress indicators, rather than being a full comprehensive report (like 10-K or IR) or a transcript (CT). Since it is an announcement of interim data, 'ER' (Earnings Release, often used broadly for period results/updates) is the most fitting category among the choices, although 'RPA' (Report Publication Announcement) could be considered if the text was purely announcing the availability of a separate, attached report. However, this text contains the actual data highlights, making 'ER' more appropriate for the substance of the news. FY 2020
2020-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.